GPR109A (HCAR2) Agonists for Neurodegeneration

Introduction

GPR109A, also known as HCAR2 (Hydroxycarboxylic Acid Receptor 2) or NIACR1 (Niacin Receptor 1), is a G-protein coupled receptor that functions as the receptor for butyrate (a short-chain fatty acid produced by gut bacteria) and niacin (vitamin B3). This receptor serves as a critical link between the gut microbiome and brain health, making it an attractive target for neurodegenerative disease therapy. ^{1GPR109A: the butyrate receptor linking gut microbiome to brain health2020 · Cell Host Microbe · PMID 32272060Open reference}

GPR109A Biology

GPR109A is encoded by the HCAR2 gene and is a Gi-protein coupled receptor. Key features include:

• Endogenous Ligands: Butyrate, niacin (vitamin B3), beta-hydroxybutyrate

• Gi-coupled: Inhibits adenylate cyclase, reducing cAMP

• High Expression: Adipose tissue, immune cells (macrophages, neutrophils), brain (microglia, neurons)

• Anti-inflammatory: Activation reduces pro-inflammatory cytokine production

The receptor is highly expressed on immune cells and adipocytes, making it a key mediator of systemic anti-inflammatory effects that can influence brain function. ^{2GPR109A activation and neuroinflammation in Alzheimer's disease2018 · J Alzheimers Dis · PMID 29614679Open reference}

Mechanism of Action

GPR109A agonists work through gut-brain axis modulation and direct neuroprotection:

flowchart TD
    classDef blue fill:#0a1929,stroke:#333,stroke-width:1px
    classDef orange fill:#3e2200,stroke:#333,stroke-width:1px
    classDef green fill:#0e2e10,stroke:#333,stroke-width:1px
    classDef red fill:#3b1114,stroke:#333,stroke-width:1px
    classDef purple fill:#1a0a1f,stroke:#333,stroke-width:1px

    A["GPR109A Agonist<br/>(Butyrate, Niacin)"]:::blue --> B["GPR109A<br/>Activation"]

    B --> C["Gi-Protein<br/>Signaling"]:::orange
    C --> D["cAMP<br/>Reduction"]

    D --> E["PKA<br/>Inhibition"]
    E --> F["Reduced NF-kappaB<br/>Activation"]:::green

    F --> G["TNF-alpha, IL-1beta<br/>Reduction"]:::green
    F --> H["IL-10<br/>Increase"]:::green

    G --> I["Microglial<br/>De-activation"]:::green

    J["Vagus Nerve<br/>Signaling"]:::purple --> K["Brainstem<br/>Nuclei"]
    K --> L["Cortical<br/>Modulation"]:::green

    M["Blood-Brain<br/>Barrier"] -.-> B
    M --> N["Direct CNS<br/>Effects"]
    N --> O["Neuronal<br/>Protection"]:::green

Key Mechanisms

1. Systemic Anti-inflammation: GPR109A activation on macrophages and neutrophils reduces pro-inflammatory cytokine production (TNF-α, IL-1β, IL-6), decreasing peripheral inflammation that can cross the BBB. ^{2GPR109A activation and neuroinflammation in Alzheimer's disease2018 · J Alzheimers Dis · PMID 29614679Open reference}

2. Gut-Brain Signaling: Butyrate produced by gut bacteria can activate GPR109A on vagal afferents, transmitting anti-inflammatory signals to the brain.

3. Microglial Modulation: Direct activation of microglial GPR109A shifts cells toward anti-inflammatory phenotype.

4. Neuroprotection: Beta-hydroxybutyrate (a ketone body) also activates GPR109A, providing metabolic support during neurodegeneration.

Therapeutic Potential

Alzheimer’s Disease

GPR109A agonists may benefit AD through:

• Reduction of chronic neuroinflammation

• Amyloid plaque modulation

• Support of cognitive function

• Metabolic support via beta-hydroxybutyrate

Parkinson’s Disease

GPR109A is particularly relevant for PD:

• High expression in substantia nigra

• Protection of dopaminergic neurons via vagal signaling

• Reduction of gut-derived inflammation

• Potential to modulate alpha-synuclein pathology

Other Applications

• Multiple Sclerosis

• Stroke

• Traumatic Brain Injury

• Depression (comorbid with neurodegeneration)

Clinical Development

GPR109A agonists are in various stages of development:

Drug Properties

Side Effects

• Niacin: Flushing, gastrointestinal distress

• Butyrate: Odor, gastrointestinal effects

• Generally well-tolerated at therapeutic doses